We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling
News

CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling

CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling
News

CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and prospective biomarkers of protein kinase targets.

CST's PhosphoScan™ phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures™) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy.

The PhosphoScan™ technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan™ may enable biomarker assays for target validation and kinase inhibitor clinical development.

"Our PhosphoScan™ pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors," said Christopher Bunker, CST's Director of Business Development.

"We are able to use PhosphoScan™ to deliver focused, in-depth Phospho-Signatures™ of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan™, and this can enable CST to translate PhosphoScan™ discoveries into validated biomarker assays."
Advertisement